Antibody Response after Second-Dose of Sputnik V, ChAdOxl-nCOV, and BBIBP-CorV in the Iranian General Population

Résumé fourni par la source

Abstract Background: Effective and safe vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important tool for controlling the COVID-19 pandemic. Emergency vaccination with Sputnik V, ChAdOx1-nCOV, and BBIBP-CorV candidate vaccines in Iran has started on February 17, 2021. Hence, in the current work, we compare anti-spike IgG responses in the general population following two vaccine doses with Sputnik V, ChAdOx1-nCOV, and BBIBP-CorV vaccines in Iran. Methods: We measured Anti-spike IgG responses using an Enzyme-linked immunosorbent assay among 165 healthy adult volunteers with no known history of COVID-19 aged 21–78 years in 21 days after the second dose of Sputnik V, ChAdOx1-nCOV, and BBIBP-CorV vaccines. The primary aim was to analyze anti-spike IgG response in three types of vaccines and its correlation to age, and sex. Results: Of the 165 participants, 151 (91.5%) had seropositivity for anti-spike IgG. The seropositivity rate of Sputnik V, ChAdOx1-nCOV and BBIBP-CorV recipients were 89.6%, 96.3 and 91.2, respectively, with a p-value of 0.588. The anti-spike IgG titre was higher among ChAdOx1-nCOV recipients (median 320 interquartile ranges (IQR) 110.3–320 Binding Antibody Units (BAU)/mL) than among Sputnik V (median 257.4 IQR 136.9–320 BAU/mL) and BBIBP-CorV (median 222.5 IQR 95.07–320 BAU/mL) recipients, but without significance (p = 0.377). Conclusions: Findings from this study demonstrate that the both anti-spike IgG titer and seropositivity rate were higher in ChAdOx1-nCOV recipients than in Sputnik V and BBIBP-CorV recipients. There was no notable difference in anti-spike IgG titer and seropositivity rate with regard to age, sex, and vaccine type.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.